Business
Appointment of Corporate Adviser and Broker
Appointment of Corporate Adviser and Broker.
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\n\n \n \n \n \n \n \nEDX Medical Group PLC - Appointment of Corporate Adviser and Broker\n \nEDX Medical Group PLC · EDX\n \n19 June 2023\n \nEDX Medical Group PLC (\"EDX Medical\" or the \"Company\"), which develops innovative digital diagnostic products and services enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases, is pleased to announce the appointment of Oberon Capital as the Company's Corporate Adviser and sole broker with immediate effect. Oberon Capital is a trading name of Oberon Investments Limited.\n \nContacts:\n\n\n\n\nEDX Medical PLC\n\n\n\n\n\n\n\nDr Mike Hudson (Chief Executive Officer)\n\n\n+44 (0)7812 345 301\n\n\n\n\n \n\n\n\n\n\n\n\nOberon Capital\n\n\n\n\n\n\n\nNick Lovering (Corporate Adviser)\nAdam Pollock (Corporate Broking)\nMike Seabrook (Corporate Broking)\n\n\n+44 (0)20 3179 5300\n\n\n\n\n\n\n\n\n\n\n\n\nMedia House International\n\n\n\n\n\n\n\nRamsay Smith (Director)\n \nGary McQueen (Senior Consultant)\n\n\n+44 (0)7788 414856\[email protected]\n+ 44 (0)7834 694609\[email protected]\n\n\n\n\n \nNotes for Editors:\nAbout EDX Medical Group\nwww.edxmedical.co.uk\nEDX Medical Group PLC develops innovative digital diagnostic products and services, enabling cost effective and timely delivery of personalised treatment for cancer, heart disease, neurology and infectious diseases. The company is listed on the Access Segment of the AQSE Growth Market (TIDM: EDX).\nEDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.\nBy translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost-effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.\nEDX Medical Group operates a molecular biology and diagnostics laboratory in Cambridge, UK, and a 100%-owned subsidiary \"Tor...